media – Page 3 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

The Pure Generic Drug Giant No Longer Exists

A new wave of upheaval and transformation has long since begun. Sun Pharmaceutical, India’s largest generic drugmaker, is acquiring Organon for $117.5 billion — the largest overseas acquisition in Indian pharmaceutical history — revealing the anxiety gripping the generic drug industry. With buyer consolidation in the U.S. market, persistent pricing pressure, and intensifying competition, even global generic giants are being swept along by industry trends, saying goodbye to the era of “easy money” in generics. As Sun Pharma Chairman Dilip Shanghvi stated, ‘This is a critical step in our strategic transformation. Organon’s specialty drug assets will help us escape the quagmire of generic price wars and build a sustainable growth engine.’ Before Sun Pharma, another generic giant, Teva Pharmaceutical, had already staged a turnaround through innovation-driven transformation, with its stock rising nearly 240% since 2024. These signals collectively point to a fact: the global generic drug industry is undergoing a ...
- Source: drugdu
- 62
- May 18, 2026
Ten departments, including the State Administration of Traditional Chinese Medicine, are cracking down on illegal and irregular practices related to traditional Chinese medicine.

Recently , ten departments, including the State Administration of Traditional Chinese Medicine, jointly convened a meeting to launch a special campaign to address illegal and irregular practices in traditional Chinese medicine (TCM) medical practice. This year-long campaign will severely crack down on illegal medical practices under the guise of TCM health preservation and disease treatment, false advertising and live-streaming sales using the name of TCM, and illegal use of medical insurance funds, among other illegal and irregular activities that harm the health rights of the public. In the short term, some small and medium-sized TCM institutions and health preservation companies that rely on false advertising, illegal medical practice, and illegal insurance fraud will face closure and penalties, and related concept stocks may experience a short-term correction, impacting market sentiment to some extent. However, in the long term, the special campaign will eliminate the “bad apples” in the industry, break the ...
- Source: drugdu
- 53
- May 18, 2026
Breaking News! Results of Two Studies on Smegglutinin Announced

The 33rd European Congress on Obesity (ECO 2026) was recently held in Istanbul, Türkiye. Novo Nordisk unveils two key data points: Higher doses of Wegovy injection (semaglutide 7.2 mg) resulted in nearly 28% weight loss in early responders; Wegovy oral tablets achieved a 21.6% weight loss and significantly improved physical activity in early responders. These two sets of data indicate that smegglutide has the best performance in its class in terms of comprehensive benefits such as weight loss, muscle health improvement, and improved mobility. 01 STEP UP subgroup analysis: Higher doses offer weight loss advantages The STEP UP trial was a 72-week, randomized, double-blind, parallel-group, placebo-controlled superiority trial designed to evaluate the efficacy and safety of semaglutide 7.2 mg as an adjunct to lifestyle interventions compared to semaglutide 2.4 mg and placebo. The trial enrolled over 1400 obese adults without type 2 diabetes. A recent subgroup analysis showed that, regardless ...
- Source: drugdu
- 55
- May 18, 2026
Synermore Biotech Receives Another International GMP Certification; Innovative Monoclonal Antibody Drug Cribi® Accelerates Global Expansion

On May 11, 2026, Synermore Biopharmaceutical (Suzhou) Co., Ltd. (“Synermore Biopharmaceutical”) announced that it had officially received the Good Manufacturing Practice (GMP) certificate issued by the Philippine Food and Drug Administration (FDA Philippines) . This is Synermore Biopharmaceutical’s second overseas GMP certification , following its acquisition of the Turkish GMP certificate at the end of 2025. This signifies that the production quality management system of its core product, Zamerovic-Mazoprevir Injection (trade name: Cribi®), continues to be recognized by overseas regulatory agencies, further accelerating its internationalization process. GMP certificate issued by the Philippine Food and Drug Administration (FDA Philippines) Krebi® is a Class I innovative drug independently developed by Synermore Biotechnology, used for passive immunization in adult individuals exposed to rabies virus. It is the first domestically produced anti-rabies cocktail monoclonal antibody that meets the recommendations of the World Health Organization (WHO) and was approved for marketing by the China National ...
- Source: drugdu
- 56
- May 18, 2026
AbbVie’s $3.9 billion drug has been approved for marketing in the country!

On May 15, the NMPA (National Medical Products Administration) announced on its website that AbbVie ‘s ectorituximab has been approved for marketing. The approved indication is for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) in combination with rituximab and lenalidomide. Previously, this marketing application had been included in the priority review pathway, accelerating its approval process. 01 A massive $3.9 billion investment to introduce next-generation innovative dual-antibody drugs. Icarutumab was originally developed by Genmab . In 2020, AbbVie and Genmab entered into a strategic collaboration worth $3.9 billion to jointly develop and commercialize three of Genmab ‘s next-generation bispecific antibody products, including Icarutumab . As an IgG1 type CD20×CD3 bispecific antibody, Icaretimab can simultaneously and precisely bind to CD3 on the surface of T cells and CD20 on the surface of B cells, effectively activating T cells and mediating their direct killing of lymphoma B ...
- Source: drugdu
- 63
- May 18, 2026
This is no small matter; CSPC Pharmaceutical Group’s new antidepressant has been submitted for its first generic version to market

Depression is a common mental illness characterized by high prevalence, high relapse rate, and high disease burden. While existing antidepressants are generally effective, unmet clinical needs remain regarding their speed of onset, remission rate, and patient adherence. Statistics show that the lifetime prevalence of depressive disorders among adults in China is as high as 6.8%, with 3.4% suffering from depression. Currently, the number of people suffering from depression is approaching 100 million, meaning one in every 14 people suffers from depression. On May 15, 2026, according to the latest information on the website of the Center for Drug Evaluation (CDE) of China, the marketing application for dextromethorphan-bupropion extended-release tablets submitted by CSPC Ouyi Pharmaceutical Co., Ltd. under Category 3 chemical drug registration was accepted. According to publicly available information , the drug’s indication is for the treatment of depression in adults . picture Publicly available information shows that dextromethorphan-bupropion extended-release ...
- Source: drugdu
- 44
- May 18, 2026
Sinopharm’s innovative biopharmaceutical, Xinfutai Plus®, has been approved for marketing. It is the first domestically produced teriparatide weekly formulation for the treatment of osteoporosis.

Recently, Sinopharm announced that its innovative biological drug, recombinant teriparatide for injection (Sinfutai Plus® ) , has been approved by the National Medical Products Administration for the treatment of osteoporosis in postmenopausal women at high risk of fractures. Osteoporosis is a systemic bone disease with a high incidence and great harm, especially among postmenopausal women. It is characterized by low bone mass and destruction of bone tissue microstructure, leading to increased bone fragility and easy fractures. According to estimates, there are currently about 90 million people with osteoporosis in China, of which about 70 million are women. The main treatment goal for osteoporosis is to reduce the risk of fractures. Teriparatide helps promote bone formation, increase bone density, and improve bone quality, providing a new option for osteoporosis patients with extremely high risk of fractures and has been recommended by domestic and international guidelines [2] . Xinfutai Plus® ( recombinant ...
- Source: drugdu
- 49
- May 18, 2026
【EXPERT Q&A】What Documents Are Required for Transitioning a Class III Medical Device from R&D to Production?

Drugdu.com expert’s response: Moving from R&D to production is essentially a “handoff” — turning laboratory technology into repeatable, controllable, and traceable mass production capability on the factory floor. The process involves a large number of documents, which are organized below by logical flow. Block 1: Documents That “Define the Product” This block answers the question: “What exactly are we making, and what standards must it meet?” First is the Product Technical Requirements, which is the core attachment of the registration certificate. It specifies all performance indicators, allowable tolerances, and test methods. All quality inspection activities on the production side are based on this document. Next are the Design & Development Input/Output documents, including intended use, functional and performance requirements, safety requirements, and applicable national/industry standards. This is the starting point for all design work. Then comes the Risk Management Report. In accordance with YY 0316 (ISO 14971), risk analysis, risk evaluation, and risk ...
- Source: drugdu
- 42
- May 18, 2026
First Generic Just Approved, Third Filing for Market Authorization!

On May 13, the CDE website showed that the third generic version of abemaciclib tablets had submitted a market authorization application, from Shandong Bionuo. Previously, Qilu Pharmaceutical and Jiangxi Kerui Pharmaceutical (a subsidiary of Qingfeng Pharmaceutical) had submitted market authorization applications for abemaciclib tablets in December 2024 and January 2025, respectively. Among them, Kerui Pharmaceutical’s abemaciclib tablets received approval on May 6, becoming the first domestic generic. Abemaciclib is a CDK4/6 inhibitor developed by Eli Lilly. It induces senescence and apoptosis of breast cancer cells by inhibiting cyclin D. The abemaciclib tablet was first approved in the United States in September 2017 and was approved in China in December 2020. According to Lilly’s 2025 annual report, global sales of abemaciclib reached $5.723 billion. In China, data from Mosheng Pharma shows that abemaciclib’s sales in the domestic all-terminal hospital market exceeded RMB 800 million in 2025. Behind this stable market growth ...
- Source: drugdu
- 77
- May 15, 2026
A $15.2 billion deal, the top player blows the show!

At a time when the industry is repeatedly plagued by anxiety about going global, Hengrui has made a stunning move with a deal worth tens of billions of US dollars! On May 12, Hengrui Medicine and Bristol-Myers Squibb (BMS) announced that they have entered into a global strategic collaboration and licensing agreement to jointly advance 13 early-stage projects covering oncology, hematology and immunology, with a potential total transaction value of approximately US$15.2 billion. The significance of this collaboration goes far beyond the monetary amount; the true core of this “deep-water bomb” lies in the dual innovations in the cooperation model and payment structure. This agreement is not the typical one-off deal for a single pipeline in the industry, but rather it directly extends and broadens the scope of cooperation—Hengrui has the option to jointly develop specific projects and has the opportunity to jointly carry out specific commercialization activities with BMS ...
- Source: drugdu
- 88
- May 15, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.